Nykode Therapeutics AS (FRA:5VB)

Market Cap	86.31M +46.1%
Revenue (ttm)	385.82K -95.1%
Net Income	-10.42M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	500
Open	0.1995
Previous Close	0.1995
Day's Range	0.1995 - 0.1995
52-Week Range	0.0859 - 0.3028
Beta	n/a
RSI	49.39
Earnings Date	Apr 17, 2026

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 i...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 59
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5VB

Financial Performance

In 2025, Nykode Therapeutics AS's revenue was $453,000, a decrease of -95.05% compared to the previous year's $9.16 million. Losses were -$12.24 million, -68.47% less than in 2024.

Financial numbers in USD